Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-06-13 | Lipidor | Lipidor offentliggör slutligt utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-13 | Lipidor | Lipidor announces final outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-12 | Lipidor | Lipidor announces preliminary outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-12 | Lipidor | Lipidor offentliggör preliminärt utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-07 | Lipidor | Sista dag för handel med uniträtter i Lipidors företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-07 | Lipidor | Last day of trading in unit rights in Lipidor's rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-05 | Lipidor | Kommuniké från årsstämma i Lipidor AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-05 | Lipidor | Bulletin from the Annual General Meeting of Lipidor AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-29 | Lipidor | Lipidor invites to digital presentations with Q&A | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-29 | Lipidor | Lipidor bjuder in till digitala investerarpresentationer med möjlighet att ställa frågor | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-29 | Lipidor | Idag inleds teckningsperioden i Lipidors företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-29 | Lipidor | Today the subscription period in Lipidor's rights issue begins | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-24 | Lipidor | Lipidor publishes prospectus due to upcoming rights issue of units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-24 | Lipidor | Lipidor offentliggör prospekt med anledning av förestående företrädesemission av units | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-22 | Lipidor | Lipidor AB (publ) publishes interim report for Q1 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-22 | Lipidor | Lipidor AB (publ) offentliggör delårsrapport för Q1 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-21 | Lipidor | Bulletin from the Extraordinary General Meeting of Lipidor AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-21 | Lipidor | Kommuniké från extra bolagsstämma i Lipidor AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-20 | Lipidor | Lipidor: Frågestund med Ola Holmlund | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Lipidor | Lipidor AB (publ) offentliggör årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Lipidor | Lipidor AB (publ) publishes annual report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-13 | Lipidor | Rättelse: Lipidor: Bolagspresentation med Ola Holmlund | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-13 | Lipidor | Lipidor: Bolagspresentation med Ola Holmlund | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-07 | Lipidor | NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-07 | Lipidor | KALLELSE TILL ÅRSSTÄMMA I LIPIDOR AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Lipidor | Lipidor AB meddelar nytt datum för publicering av årsredovisning för 2023 | Financial Calendar | Ladda ner | Visa Stäng |
|
||||
2024-04-22 | Lipidor | Lipidor AB announces new date for publication of Annual Report 2023 | Financial Calendar | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Lipidor | NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the “EGM”) on 21 May 2024 at 10.00 CEST at Fredersen Advokatbyrå, Birger Jarlsgatan 8 in Stockholm. Registration starts at 09.30 CEST. NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. Right to participate Nominee-registered shares Proxy Proposal of agenda Proposals Election of Chairman of the Meeting (item 2) Resolution on a) amendment of the Articles of Association, and b) approval of the Board of Directors’ resolution on a new issue of units with pre-emption rights for existing shareholders (item 7 a)–b)) a) Resolution on amendment of the Articles of Association The limits for the share capital in § 4 of the Articles of Association are proposed to be amended as follows: “ § 4 Share capital “ § 5 Number of shares b) Resolution on approval of the Board of Directors’ resolution on a new issue of units with pre-emption rights for existing shareholders 1. The share capital is increased with not more than SEK 57,953,726 through an issue of not more than 1,159,074,520 shares. Furthermore, 289,768,630 warrants of series TO 2 (“ Warrants ”) are issued. One (1) Warrant entails a right to subscribe for one (1) new share whereby the Company’s share capital can, additionally, increase with not more than SEK 14,488,431.50 and the number of shares can, additionally, increase with not more than 289,768,630 shares. 2. The new shares and Warrants will be issued as so-called units. Each unit consists of four (4) shares and one (1) Warrant. 3. Possession of one (1) share on the record date on 27 May 2024, entitles the holder to ten (10) unit rights. One (1) unit right entitle the holder to subscribe for one (1) unit. 4. The subscription price for each unit shall amount to SEK 0.20. The subscription price for each share shall thus amount to SEK 0.05. The Warrants are issued free of charge. 5. The part of the subscription price for the shares that exceeds the quotient value of the share shall be added to the non-restricted share premium reserve and the part of the subscription price for the shares which are subscribed for through exercising the Warrants which exceeds the quotient value of the share shall be added to the non-restricted share premium reserve. 6. The right to subscribe for units shall accrue with pre-emptions rights to those who, as of the record date on 27 May 2024, own shares in the Company. 7. If all units are not subscribed for with the support of pre-emption rights, the Board of Directors shall resolve on allotment, within the limits of the maximum amount set out in the Rights Issue. Allotment will be determined on the following grounds: i. firstly, to those who have subscribed for units with the support of unit rights and who wish to subscribe for additional units (regardless of whether they were shareholders on the record date or not), pro rata their subscription with the support of unit rights, and, to the extent that this cannot be done, by drawing lots; ii. secondly, to others who have registered an interest in subscribing for units without the support of unit rights (and who are not covered by point i) above), pro rata their notified interest, and, to the extent that this cannot be done, by drawing lots; iii. thirdly, to persons who have provided guarantee commitments regarding subscription of units, pro rata their guaranteed commitments. 8. The subscription period shall take place from and including 29 May 2024 up to and including 12 June 2024. 9. Subscription by use of unit rights shall be made through payment no later than on 12 June 2024. Subscription without use of unit rights shall be made on a subscription list whereby payment shall be made no later than three banking days from when the notification regarding allotment was sent. 10. The Board of Directors shall be entitled to extend the subscription and payment periods. Such extension should be made no later than on the last day of the subscription period. 11. The new shares shall entitle to dividend on the first record date for dividend regarding shares which takes place after they have been registered in the Company’s share register. 12. Possession of one (1) Warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price per share amounting to SEK 0.10, however, not less than the quota value of the Company’s share, during a period of two (2) weeks from and including the seventh trading day after the Company informs through a press release about the results of the phase III study of the Company’s drug candidate AKP02G2 or, in the absence of such press release, during the period from and including 15 August 2025 to and including 29 August 2025. 13. For the Warrants applies, in addition to what is stated in this resolution, the complete terms and conditions for the Warrants. 14. The CEO, or the person he or she appoints, shall be authorised to make the minor adjustments in the resolution and the terms and conditions that may prove necessary in connection with registration and execution. Resolution in accordance with items 7 a)–b) are adopted as one resolution. Resolution to amend the Articles of Association (item 8) “ § 10 Holding a General Meeting Majority requirements Further information Proxy form, the Board’s complete proposals as well as other relevant documents will be made available by the Company and at the Company’s website at least three weeks before the EGM. The documents will be sent to shareholders who request it and provide their postal address. The shareholders are reminded of their right of information according to Chapter 7, Section 32 of the Swedish Companies Act. The Company has its registered office in Stockholm. Processing of personal data Stockholm, April 2024 |
||||
2024-04-10 | Lipidor | KALLELSE TILL EXTRA BOLAGSSTÄMMA I LIPIDOR AB (PUBL) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Lipidor | Lipidor beslutar om företrädesemission om cirka 58,0 MSEK och ingår avtal om co-investering vilka säkerställer finansiering för genomförandet av kommande fas III-studie | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-10 | Lipidor | Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-26 | Lipidor | Lipidor slutför planerad avyttring av aktier i Emollivet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-26 | Lipidor | Lipidor completes planned divestment of shares in Emollivet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-21 | Lipidor | Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-21 | Lipidor | Lipidor meddelar godkännande för start av klinisk Fas III-studie med psoriasiskandidaten AKP02G2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-06 | Lipidor | Lipidor adds capital through sale of shares | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-06 | Lipidor | Lipidor tillförs kapital genom försäljning av andelar | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Lipidor | Lipidor AB (publ) publishes year-end report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Lipidor | Lipidor AB (publ) offentliggör bokslutskommuniké för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Lipidor | Lipidor genomför affär för 1,7 MSEK avseende patent relaterat till djursegmentet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-24 | Lipidor | Lipidor completes SEK 1.7 million sale of animal segment patent | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Lipidor | Lipidor tillförs 1,1 MSEK genom försäljning av andelar i intresseföretag samt upptagande av lån | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Lipidor | Lipidor adds 1.1 MSEK through sale of shares in associated company and agreement of loan | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Lipidor | Lipidor ansöker till den indiska läkemedelsmyndigheten om att få starta en Fas III-studie av AKP02G2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Lipidor | Lipidor applies to the Indian Medical Products Agency to start a Phase III study of AKP02G2 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-05 | Lipidor | Lipidor presenterar valberedningen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-05 | Lipidor | Lipidor presents Nomination Committee | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Lipidor | Lipidor byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Lipidor | Lipidor changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-22 | Lipidor | Lipidor AB (publ) publishes interim report for Q3 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-22 | Lipidor | Lipidor AB (publ) offentliggör delårsrapport för tredje kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Lipidor | Lipidor lämnar in en ny patentansökan | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-27 | Lipidor | Lipidor submits new patent application | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Lipidor | Lipidor förlänger och utökar samarbetet med RELIFE | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Lipidor | Lipidor extends and expands cooperation with RELIFE | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-20 | Lipidor | Lipidor tecknar avtal för klinisk fas III-studie | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-20 | Lipidor | Lipidor signs agreement for clinical phase III study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Lipidor | Rättelse: Lipidor AB (publ) offentliggör delårsrapport för andra kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Lipidor | Correction: Lipidor AB (publ) publishes interim report for Q2 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Lipidor | Lipidor AB (publ) publishes interim report for Q2 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Lipidor | Lipidor AB (publ) offentliggör delårsrapport för andra kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Lipidor | Lipidor – Besked om kortsiktig finansiering | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Lipidor | Lipidor – Announcement of short-term funding | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-22 | Lipidor | Lipidor – Läkemedelsverket bekräftar den kliniska planen för ny version av AKP02 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-22 | Lipidor | Lipidor – Swedish Medical Products Agency confirms clinical plan for new version of AKP02 | Pressreleaser | Ladda ner | Visa Stäng |
|